Securities code: 300006 securities abbreviation: Chongqing Lummy Pharmaceutical Co.Ltd(300006) Announcement No.: 2021-089 Chongqing Lummy Pharmaceutical Co.Ltd(300006)
Announcement on resolutions of the 21st Meeting of the 5th board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The 21st Meeting of the 5th board of directors of Chongqing Lummy Pharmaceutical Co.Ltd(300006) (hereinafter referred to as “the company”) was held in the conference room on the 13th floor of the company’s headquarters on Thursday, December 30, 2021 by means of on-site meeting and communication voting. The meeting notice was sent to all directors by means of on-site notice and communication after the company held the second extraordinary general meeting in 2021. This meeting is an emergency interim meeting. According to the rules of procedure of the board of directors, if the situation is urgent and it is necessary to convene an interim meeting of the board of directors as soon as possible, the meeting notice can be sent by telephone or other oral means at any time. There were 8 directors who should attend the meeting, 8 actually attended the meeting, and the company’s supervisors and senior managers attended the meeting as nonvoting delegates. The meeting was convened and held in accordance with the company law of the people’s Republic of China, the articles of association and relevant laws and regulations. The meeting was presided over by Mr. Leng Xuefeng, vice chairman of the company, who explained the temporary convening of the board of directors. After deliberation and written voting by the directors present at the meeting, the following resolutions were formed:
1、 The proposal on electing the chairman of the company and changing the legal representative was deliberated and adopted
The board of directors of the company received the written resignation report submitted by Mr. Peng Weimin, chairman of the company, after the second extraordinary general meeting of shareholders in 2021. Mr. Peng Weimin applied for resignation as chairman, director and chairman of the strategy committee of the company due to work adjustment, and no longer held any position of the company after resignation.
The board of directors of the company unanimously agreed to elect Mr. Liang Jiansheng as the chairman of the Fifth Board of directors of the company. The term of office is the same as that of the Fifth Board of directors of the company, from December 30, 2021 to June 11, 2023. The independent directors of the company expressed their independent opinions on this matter.
For details, please refer to the company’s website on the same day（ http://www.cn.info . co M. C n) the announcement on electing the chairman of the company and changing the legal representative and relevant announcements.
Voting results: 8 in favor, 0 against and 0 abstention.
2、 The proposal on adding and adjusting members of special committees under the 5th board of directors was deliberated and adopted
In order to further improve the corporate governance structure and improve the standard operation level, in accordance with the company law, the guidelines for the standardized operation of companies listed on the gem of Shenzhen Stock Exchange, the articles of association and other relevant provisions, and in combination with the actual situation of the company, the company has established a strategy committee, an audit committee, a nomination committee The composition of the remuneration and assessment committee shall be supplemented and adjusted.
The original 5th board of Directors consists of strategy committee, audit committee, nomination committee and remuneration and assessment committee. The members are as follows:
1. Members of the strategy committee: Peng Weimin (Chairman), Ms. Chen Xiaohui and Ms. Li Changbi;
2. Members of the Audit Committee: Mr. Chen Xujiang (Chairman), Mr. Leng Xuefeng and Ms. Tang Weiyan; 3. Members of the nomination committee: Mr. Leng Xuefeng (Chairman), Mr. Ou Rihua and Mr. Chen Geng; 4. Members of the remuneration and assessment committee: Mr. Chen Geng (Chairman), Mr. Hu Leibing and Mr. Chen Xujiang.
Now it is added and adjusted as follows:
1. Members of the strategy committee: Mr. Liang Jiansheng (Chairman), Mr. Leng Xuefeng, Ms. Li Changbi, Mr. Chen Xujiang and Mr. Chen Geng;
2. Members of the Audit Committee: Mr. Chen Xujiang (Chairman), Mr. Leng Xuefeng, Ms. Tang Weiyan, Mr. Chen Geng and Ms. Li Changbi;
3. Members of the nomination committee: Ms. Li Changbi (Chairman), Mr. Leng Xuefeng, Mr. Ou Rihua, Mr. Chen Geng and Mr. Chen Xujiang;
4. Members of the remuneration and assessment committee: Mr. Chen Geng (Chairman), Mr. Leng Xuefeng, Mr. Hu Leibing, Mr. Chen Xujiang and Ms. Li Changbi.
The term of office of the members of the above special committees is consistent with that of the Fifth Board of directors of the company, from December 30, 2021 to June 11, 2023.
The independent directors of the company expressed their independent opinions on this matter.
Voting results: 8 in favor, 0 against and 0 abstention.
3、 The proposal on the appointment of the company’s general counsel was deliberated and adopted
In order to meet the development needs of the company, give full play to the role of the general counsel in legal review and control in operation and management, and promote the company’s legal operation and compliance management, the company’s board of directors agreed to appoint Mr. Cui Dan, deputy general manager and Secretary of the board of directors, as the general counsel of the company. The independent directors of the company expressed their independent opinions on this matter.
For details, please refer to the company’s website on the same day（ http://www.cn.info.com..cn. ）Disclosed announcement on appointment of general counsel of the company and relevant announcements.
Voting results: 8 in favor, 0 against and 0 abstention.
It is hereby announced.
Chongqing Lummy Pharmaceutical Co.Ltd(300006) board of directors December 30, 2021
